Table 4.
Evaluation of anti-EV-D68 activity for the designed compounds.
| Compound No | R2 | EC50 (μM)a | CC50 (μM)b | SI |
|---|---|---|---|---|
| 163e |  |
2.5 ± 0.5 | 11.2 ± 15.4 | 44.5 |
| 164d |  |
0.6 ± 0.5 | 37.4 ± 6.3 | 62.3 |
| 164e |  |
0.8 ± 0.6 | 6.1 ± 2.2 | 7.6 |
| 164f |  |
1.0 ± 0.4 | 46.9 ± 5.2 | 46.9 |
| 164g |  |
1.5 ± 0.9 | 122.5 ± 30.8 | 81.7 |
| 164j |  |
0.8 ± 0.3 | 45.1 ± 13.7 | 56.4 |
| 164l |  |
1.6 ± 1.8 | 36.5 ± 3.1 | 22.8 |
| 164m |  |
2.4 ± 0.2 | 31.6 ± 4.2 | 13.2 |
| 164r |  |
0.8 ± 0.2 | 11.5 ± 6.7 | 14.4 |
| 164s |  |
1.6 ± 0.1 | 29.5 ± 1.6 | 18.4 |
cN.A. = not applicable. The results are the mean ± standard deviation of three repeats. SI = selectivity index (CC50/EC50).
a
Antiviral efficacy was determined in the CPE assay with EV-D68 US/KY/14–18953 virus and RD cells.
b
Cytotoxicity was determined using the neutral red method.